Crescent Biopharma
CBIO
28 hedge funds and large institutions have $100M invested in Crescent Biopharma in 2014 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 5 reducing their positions, and 4 closing their positions.
60% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 5
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
8% more capital invested
Capital invested by funds: $93M → $100M (+$7.08M)
4% more funds holding
Funds holding: 27 → 28 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$787K |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$715K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$353K |
| 4 |
SIM
Spark Investment Management
New York
|
+$339K |
| 5 |
Blackstone Inc
New York
|
+$130K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$204K |
| 2 |
ARTA
A.R.T. Advisors
New York
|
-$97K |
| 3 |
BPC
Banque Pictet & Cie
Geneva 73,
Switzerland
|
-$88K |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$50.1K |
| 5 |
Goldman Sachs
New York
|
-$43K |
CBIO Hedge Fund Activity: Q4 2014 in Review
28 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in Crescent Biopharma (CBIO) for Q4 2014, worth a combined $100M — up 7.6% from $93M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new CBIO positions and 4 closed out — a net gain of 1 holder — while 8 added to existing stakes and 5 trimmed.
The largest buyer was JP Morgan Chase, opening a new position worth an estimated $787K. The largest seller was Franklin Resources, cutting an estimated $204K.
- 28 institutional investors held Crescent Biopharma (CBIO) as of Q4 2014, up from 27 in Q3 2014.
- Funds reported $100M of Crescent Biopharma stock for Q4 2014, up 7.6% quarter-over-quarter.
- 5 funds opened new Crescent Biopharma positions in Q4 2014 and 4 closed out, a net change of +1 holder.
- The largest Crescent Biopharma buyer in Q4 2014 was JP Morgan Chase, an estimated $787K added.
- The largest Crescent Biopharma seller in Q4 2014 was Franklin Resources, an estimated $204K sold.
Based on aggregated 13F filings for Q4 2014.